Condition: Cardiovascular Diseases · Sponsor: Translumina Therapeutics Pvt Ltd.
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR and planned for an abbreviated (≤ 3 months) dual antiplatelet therapy (DAPT) regimen.
This description comes directly from the study's public registry record.
Diptendu Chatterjee · 9339948873 · diptenduchatterjee@translumina.in
Deepanshi Thakur · 9971954733 · deepanshithakur@translumina.in
Always discuss trial participation with your own doctor first.
| Zydus Hospitals | Ahmedabad, India | Recruiting |
| Fortis Hospital | Bangalore, India | Recruiting |
| Adesh Hospital | Bathinda, India | Recruiting |
| PGIMER | Chandigarh, India | Recruiting |
| National Heart Institute | Delhi, India | Recruiting |
| Fortis Escorts Heart Institute & Research Centre | Delhi, India | Recruiting |
| Fortis Escorts Heart Institute & Research Centre | Delhi, India | Recruiting |
| Medanta-The Medicity | Gurugram, India | Recruiting |
| Yashoda Hospitals | Hyderabad, India | Recruiting |
| Shalby Hospital | Jabalpur, India | Recruiting |
| Fortis Hospital | Kalyān, India | Recruiting |
| L.P.S Institute of Cardiology | Kanpur, India | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06412250